Mohammad Alsorogi, MD
Neurology · Louisville, KYNPI 1598974123
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $87,613 of the $111,008 with a category attached, or 78.9%. 30 manufacturers reported payments, led by AbbVie at 42.1% of the total. Reporting peaked in 2019 at $35,033 and has fallen 72.0% since, to $9,807 in 2025. Among neurology clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 471 payments — averaging $235.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$47K
- Acorda Therapeutics, Inc$21K
- MDD US Operations, LLC$21K
- Biogen$15K
- Neurocrine Biosciences, Inc.$2K
- Novartis$2K
- plus $4K from 24 others
What the payments were for
- Consulting fees$7,5707%
- Speaking & faculty fees$87,61379%
- Travel & lodging$6,6946%
- Food & beverage$7,4717%
- Education$3240%
- Gifts$1,3351%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 93 | $46,777 |
| Acorda Therapeutics, Inc | 36 | $21,276 |
| MDD US Operations, LLC | 40 | $20,670 |
| Biogen | 34 | $14,928 |
| Neurocrine Biosciences, Inc. | 12 | $1,577 |
| Novartis | 17 | $1,550 |
| Sunovion Pharmaceuticals Inc. | 109 | $1,412 |
| Amgen | 31 | $569 |
| Noctrix Health, Inc. | 1 | $327 |
| Genentech USA, Inc. | 23 | $326 |
| AstraZeneca | 8 | $262 |
| EMD Serono, Inc. | 17 | $212 |
| Teva Pharmaceuticals USA, Inc. | 5 | $145 |
| Bristol Myers Squibb | 1 | $118 |
| Mallinckrodt Enterprises LLC | 7 | $108 |
| Boston Scientific | 3 | $102 |
| E.r. Squibb & Sons, L.L.C. | 1 | $101 |
| Amneal Pharmaceuticals LLC | 5 | $95 |
| UCB, Inc. | 6 | $92 |
| Acadia Pharmaceuticals Inc | 5 | $68 |
| Merz North America, Inc. | 4 | $57 |
| Medtronic | 3 | $53 |
| SK Life Science, Inc. | 1 | $50 |
| Adamas Pharmaceuticals, Inc. | 2 | $31 |
| Lundbeck LLC | 2 | $27 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $18 |
| Pfizer | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$111,008 in reported general payments places this provider in the 90th percentile of 210 neurology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 38 | $221,897 |
| TecfideraDimethyl Fumarate | 11 | $102,228 |
| RytaryCarbidopa/Levodopa | 59 | $84,839 |
| UbrelvyUbrogepant | 17 | $15,821 |
| Modafinil | 13 | $5,111 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 116 | $3,955 |
| Entacapone | 16 | $3,078 |
| Rasagiline Mesylate | 29 | $3,017 |
| Primidone | 55 | $2,324 |
| Ropinirole ErRopinirole Hcl | 12 | $1,966 |
| Dimethyl Fumarate | 11 | $1,908 |
| Propranolol Hcl ErPropranolol Hcl | 34 | $1,712 |
| Selegiline Hcl | 11 | $1,605 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 22 | $1,550 |
| Gabapentin | 84 | $1,482 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $68 | $221,89738 claims |
| BiogenTecfidera | $14,928 | $102,22811 claims |
| Amneal Pharmaceuticals LLCRytary | $95 | $84,83959 claims |
| AbbVieUbrelvy | $46,777 | $15,82117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 210 neurology providers in Kentucky.
Other neurology in Louisville
- Brian PlatoLouisville$232K
- Kristi NordLouisville$217K
- Angela HardwickLouisville$187K
- Peter HederaLouisville$185K
- Jeffrey FrankLouisville$181K
- Tad SeifertLouisville$99K
- Michael SweeneyLouisville$71K
- Michael SowellLouisville$60K
- David RobertsonLouisville$58K
- Jenny FengLouisville$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.